Cerebral mucormycosis: intranasal route to deliver amphotericin B for effective management?

Area of Science:

• Mycology
• Infectious Diseases
• Neurology

Background:

• Cerebral mucormycosis is a life-threatening fungal infection with high mortality rates.
• Current treatments, primarily intravenous antifungals, face challenges in reaching the central nervous system effectively.
• The invasive nature of the infection necessitates novel therapeutic strategies.

Purpose of the Study:

• To evaluate the potential of intranasal drug delivery for treating cerebral mucormycosis.
• To compare intranasal administration with or as an adjunct to intravenous therapy.
• To explore improved therapeutic approaches for central nervous system fungal infections.

Main Methods:

• Literature review and analysis of existing treatment protocols for mucormycosis.
• Pharmacokinetic and pharmacodynamic considerations for intranasal drug delivery to the brain.
• Discussion of potential drug candidates and formulations for intranasal administration.

Main Results:

• Intranasal delivery may offer direct access to the central nervous system, bypassing systemic circulation limitations.
• This route could potentially reduce systemic side effects associated with high-dose intravenous antifungals.
• Combination therapy (intranasal and intravenous) might enhance therapeutic efficacy.

Conclusions:

• Intranasal administration presents a promising adjunctive or alternative route for managing cerebral mucormycosis.
• Further research, including preclinical and clinical studies, is warranted to validate this therapeutic approach.
• Optimizing drug delivery via the intranasal route could significantly improve patient outcomes in central nervous system fungal infections.